CHICAGO — In this Healio Video Perspective from the AAO meeting, Michael Nathan Cohen, MD, discusses phase 1 data investigating JNJ-81201887 gene therapy from Janssen for the treatment of geographic atrophy.
According to Cohen, JNJ-81201887 met its primary safety and tolerability endpoints in all doses evaluated. The only notable adverse event was mild inflammation in 29% of patients.